NCT05205330 - Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Refractory Metastatic Colorectal CancerSolid TumorMetastatic Microsatellite-stable Colorectal CancerMismatch Repair Protein ProficientMetastatic GI CancersGastric Cancer

Interventions

DRUG

CR6086

oral CR6086, twice a day for 14 days

BIOLOGICAL

AGEN2034

AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

Trial Locations (3)

20133

RECRUITING

Istituto Nazionale dei Tumori, Milan

35128

RECRUITING

Istituto Oncologico Veneto IRCCS, Padua

56126

RECRUITING

Azienda Ospedaliero Universitaria Pisana, Pisa